Low molecular weight heparin: Difference between revisions
(Created page with "==Background== *Trade name = Lovenox *A Low Molecular Weight Heparin (LMWH) ==Treatment== *DOSE = 1mg/kg sq bid *No need to monitor PTT and adjust dosages. ==Uses/Benefits== # ...") |
No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
#Similar mechanism of action as heparin but with predictable effect | |||
#Advantages over unfractionated heparin: | |||
##More reliable level of anticoagulation | |||
##No need for monitoring w/ PTT | |||
##Decreased incidence of HIT | |||
##Can give as oupt | |||
#Disadvantages compared to unfractionated heparin: | |||
##Renally excreted; may accumulate in pts w/ renal impairment leading to bleeding | |||
##Longer half-life | |||
==Dosing== | |||
#Renal impairment (Cr clearance <30) | |||
##Use 50% of usual dose or use UFH instead | |||
#Obesity | |||
##Weight-based dosing safe up to 190kg (no data available thereafter) | |||
==Treatment== | ==Treatment== | ||
#See: | |||
##[[DVT]] | |||
##[[PE]] | |||
##[[NSTEMI]] | |||
# DVT | ##[[STEMI | ||
# | |||
# | |||
# | |||
# | |||
# | |||
# | |||
==Source == | ==Source == | ||
Tintinalli | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] | ||
Revision as of 07:23, 21 October 2011
Background
- Similar mechanism of action as heparin but with predictable effect
- Advantages over unfractionated heparin:
- More reliable level of anticoagulation
- No need for monitoring w/ PTT
- Decreased incidence of HIT
- Can give as oupt
- Disadvantages compared to unfractionated heparin:
- Renally excreted; may accumulate in pts w/ renal impairment leading to bleeding
- Longer half-life
Dosing
- Renal impairment (Cr clearance <30)
- Use 50% of usual dose or use UFH instead
- Obesity
- Weight-based dosing safe up to 190kg (no data available thereafter)
Treatment
Source
Tintinalli